| | GI disorder | Treatment | MTC estimate (95% CI) of different treatment course | | ≤12 weeks | >12 weeks | ≥26 weeks | ≥52 weeks |
| | Nausea |
| | No. of studies | | 4 | 12 | 14 | 5 | | |
Placebo (ref.) | | | | | | EX10BID | 29.52
(2.89, 301.80) | 7.95
(3.30, 19.17) | 5.12
(2.16, 12.12) | 123.84
(19.81, 1145.96) | | | EX2QW | — | 1.82 (0.42, 7.89) | 3.53 (0.60, 20.61) | — | | | EX5BID | 6.87 (0.37, 128.05) | 3.27 (0.72, 14.78) | 3.37
(1.12, 10.11) | — | | | LIR06 | — | 3.00 (0.22, 40.79) | — | 3.60
(1.22, 12.13) | | | LIR12 | — | 3.31 (0.25, 44.56) | 10.08
(1.78, 57.09) | 5.45
(1.99, 17.62) | | | LIR18 | — | 4.08 (0.31, 54.22) | 3.68 (0.96, 14.14) | 6.75
(2.47, 22.15) | | | CT | — | 0.42 (0.09, 1.90)
| 0.30 (0.09, 0.99)
| 1.19 (0.42, 3.89)
|
| | Vomiting |
| | No. of studies | | 2 | 11 | 14 | 5 | | |
Placebo (ref.) | | | | | | EX10BID | 1.97 (0.26, 15.15) | 17.25
(4.48, 72.75) | 4.07
(1.53, 10.83) | 21.28 (0.72, 1095.54) | | | EX2QW | — | 16.54
(1.69, 167) | 1.87 (0.29, 12.12) | — | | | EX5BID | — | 5.92 (0.82, 42.91) | 4.51
(1.35, 15.08) | — | | | LIR06 | — | 30.14
(1.26, 724.88) | — | 17.90
(1.06, 703.45) | | | LIR12 | — | 39.92
(1.71, 951.46) | 8.06 (0.73, 89.06) | 14.43 (0.94, 506.23) | | | LIR18 | — | 63.82
(2.74, 1513.23) | 3.81 (0.83, 17.61) | 15.77
(1.03, 557.80) | | | CT | — | 6.09 (0.79, 46.99) | 0.44 (0.11, 1.69)
| 3.66 (0.2, 131.37) |
| | Diarrhea |
| | No. of studies | | 1 | 10 | 12 | 5 | | |
Placebo (ref.) | | | | | | EX10BID | 8.22 (0.39, 172.98)
| 1.95 (0.73, 5.19) | 2.13
(1.22, 3.6) | 8.76
(2.00, 38.43) | | | EX2QW | — | 4.09 (0.57, 29.47) | 2.2 (0.85, 5.37) | — | | | EX5BID | 10.88 (0.54, 219.83) | 1.99 (0.32, 12.30) | 1.7 (0.94, 3.09) | — | | | LIR06 | — | 2.49 (0.16, 39.90) | — | 3.73
(1.15, 12.15) | | | LIR12 | — | 3.29 (0.20, 53.46) | 29.78
(6.91, 150.05) | 3.28
(1.11, 9.75) | | | LIR18 | — | 3.73 (0.23, 59.56) | 2.53
(1.14, 5.28) | 4.57
(1.53, 13.61) | | | CT | — | 1.67 (0.20, 13.76)
| 0.85 (0.41, 1.66)
| 1.80 (0.61, 5.29)
|
|
|
